A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of Participants with Non-Serious Adverse Events and Serious Adverse Events
2 years
Yes
Tatsuya Sasaki
Study Director
Oncology Clinical Development Section, Japan / Asia Clinical Research, Product Creation Unit, Eisai Product Creation System
Japan: Ministry of Health, Labor and Welfare
E7080-J081-208
NCT01728623
August 2012
February 2015
Name | Location |
---|